Overexpression of VEGF165b, an Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Leads to Insufficient Angiogenesis in Patients with Systemic Sclerosis

Circulation Research

Volumn 109, Issue 3, 2011, Pages

  Manetti, Mirko ^a   Guiducci, Serena ^a   Romano, Eloisa ^a   Ceccarelli, Claudia ^a   Bellando Randone, Silvia ^a   Conforti, Maria Letizia ^a   Ibba Manneschi, Lidia ^a   Matucci Cerinic, Marco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

angiogenesis; antiangiogenic agents; peripheral vascular diseases; scleroderma; systemic sclerosis; vascular endothelial growth factor A

Indexed keywords

ANGIOGENIC PROTEIN; MESSENGER RNA; RECOMBINANT PROTEIN; RECOMBINANT VASCULOTROPIN 165; SERINE ARGININE PROTEIN 55; SERINE ARGININE RICH PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN 165B; VASCULOTROPIN 165B ANTIBODY; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2; NUCLEAR PROTEIN; PHOSPHOPROTEIN; SFRS6 PROTEIN, HUMAN; VASCULOTROPIN A; VASCULOTROPIN B; VEGFA PROTEIN, HUMAN; VEGFB PROTEIN, HUMAN;

ADULT; ANGIOGENESIS; ANGIOGENESIS IMPAIRMENT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CAPILLARY PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY CELL; KERATINOCYTE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN OVEREXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN VARIANT; SIGNAL TRANSDUCTION; SKIN; SKIN BIOPSY; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; UPREGULATION; VASCULAR DISEASE; ALTERNATIVE RNA SPLICING; CELL CULTURE; CULTURE MEDIUM; CYTOLOGY; DERMIS; DRUG EFFECT; GENE EXPRESSION; GENETICS; ISCHEMIA; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; VASCULARIZATION;

ALTERNATIVE SPLICING; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DERMIS; ENDOTHELIAL CELLS; GENE EXPRESSION; HUMANS; ISCHEMIA; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PHOSPHORYLATION; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR B; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79961031252     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.242057     Document Type: Article

References (35)

1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557-567. (Pubitemid 46348510)
2. LeRoy EC. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am. 1996;22:675-694.
3. Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M. Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med. 2010;14:1241-1254.
4. Guiducci S, Giacomelli R, Matucci-Cerinic M. Vascular complications of scleroderma. Autoimmun Rev. 2007;6:520-523. (Pubitemid 47374612)
5. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395. (Pubitemid 30208155)
6. Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, Michel BA, Gay RE, Müller-Ladner U, Matucci-Cerinic M, Plate KH, Gassmann M, Gay S. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004;95:109-116. (Pubitemid 38931842)
7. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991;5:1806-1814.
8. Neufeld G, Cohen T, GitayGoren H, Poltorak Z, Tessler S, Sharon R, Gengrinovitch S, Levi BZ. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev. 1996;15:153-158. (Pubitemid 26236112)
9. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;62:4123-4131. (Pubitemid 34791084)
10. Qiu Y, Hoareau-Aveilla C, Oltean S, Harper SJ, Bates DO. The antiangiogenic isoforms of VEGF in health and disease. Biochem Soc Trans. 2009;37(part 6):1207-1213.
11. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui TG, Sugiono M, Waine E, Perrin R, Foster R, Digby-Bell J, Shields JD, Whittles CE, Mushens RE, Gillatt DA, Ziche M, Harper SJ, Bates DO. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64:7822-7835. (Pubitemid 39446915)
12. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic retinopathy is associated with a switch in splicing from anti-to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia. 2005;48:2422-2427. (Pubitemid 41618935)
13. Varey AH, Rennel ES, Qiu Y, Bevan HS, Perrin RM, Raffy S, Dixon AR, Paraskeva C, Zaccheo O, Hassan AB, Harper SJ, Bates DO. VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro-and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer. 2008;98:1366-1379. (Pubitemid 351543576)
14. Pritchard-Jones RO, Dunn DB, Qiu Y, Varey AH, Orlando A, Rigby H, Harper SJ, Bates DO. Expression of VEGF (xxx) b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer. 2007;97:223-230. (Pubitemid 47057469)
15. Ergorul C, Ray A, Huang W, Darland D, Luo ZK, Grosskreutz CL. Levels of vascular endothelial growth factor-A165b (VEGF-A165b) are elevated in experimental glaucoma. Mol Vis. 2008;14:1517-1524.
16. Konopatskaya O, Churchill AJ, Harper SJ, Bates DO, Gardiner TA. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularisation in mice. Mol Vis. 2006;12:626-632. (Pubitemid 43786776)
17. Rennel E, Waine E, Guan H, Schuler Y, Leenders W, Woolard J, Sugiono M, Gillatt D, Kleinerman E, Bates D, Harper S. The endogenous antiangiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer. 2008;98:1250-1257. (Pubitemid 351481687)
18. Peiris-Pages M, Harper SJ, Bates DO, Ramani P. Balance of proversus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth. J Pathol. 2010;222:138-147.
19. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO. Expression of proand anti-angiogenic isoforms of VEGF is differentially regulated by known splicing and growth factors. J Cell Sci. 2008;121:3487-3495.
20. Rennel ES, Harper SJ, Bates DO. Therapeutic potential of manipulating VEGF splice isoforms in oncology. Future Oncol. 2009;5:703-712.
21. Mackiewicz Z, Sukura A, Povilenaite D, Ceponis A, Virtanen I, Hukkanen M, Konttinen YT. Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. Clin Exp Rheumatol. 2002;20:641-646. (Pubitemid 35243776)
22. Davies CA, Jeziorska M, Freemont AJ, Herrick AL. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol. 2006;37:190-197. (Pubitemid 43099839)
23. Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, Gay RE, Michel BA, Bruhlmann P, Muller-Ladner U, Gay S, Matucci-Cerinic M. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res. 2002;4:R11.
24. Hummers LK, Hall A, Wigley FM, Simons M. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol. 2009;36:576-582.
25. Choi JJ, Min DJ, Cho ML, Min SY, Kim SJ, Lee SS, Park KS, Seo YI, Kim WU, Park SH, Cho CS. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol. 2003;30:1529-1533.
26. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573-1576. (Pubitemid 32660630)
27. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr., Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202-205. (Pubitemid 18073738)
28. Denton CP, Abraham DJ. Transforming growth factor-/3 and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol. 2001;13:505-511. (Pubitemid 33070969)
29. D'Alessio S, Fibbi G, Cinelli M, Guiducci S, Del Rosso A, Margheri F, Serratì S, Pucci M, Kahaleh B, Fan P, Annunziato F, Cosmi L, Liotta F, Matucci-Cerinic M, Del Rosso M. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum. 2004;50:3275-3285. (Pubitemid 39372005)
30. Margheri F, Manetti M, Serratì S, Nosi D, Pucci M, Matucci-Cerinic M, Kahaleh B, Bazzichi L, Fibbi G, Ibba-Manneschi L, Del Rosso M. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional,/32 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum. 2006;54:3926-3938. (Pubitemid 44955896)
31. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
32. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9:777-794. (Pubitemid 43116546)
33. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22. (Pubitemid 29038270)
34. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling: in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359-371.
35. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25. (Pubitemid 27076453)